secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001549595-24-000041
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix announces first clinical responses in brain for BTK degrader NX-5948
--------------------------------------------------------------------------

- NX-5948 detected in CSF from all available samples, showing brain penetration.
- CLL patient with CNS involvement achieved partial response by week 24 and cleared tumor cells from CSF.
- PCNSL patient with MYC rearrangement had complete regression of three lesions at week 8, but progressed by week 16.
- Data presented at AACR 2024; NX-5948 is an oral BTK degrader in Phase 1a/1b for B cell malignancies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/0001549595-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/nrix-20240409.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer